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ABSTRACT 
Lack of safe and effective adjuvants is a major hindrance to the development of efficacious 
vaccines.  Signaling via CD40 pathway leads to enhanced antigen processing and 
presentation, nitric oxide expression, pro-inflammatory cytokine expression by antigen 
presenting cells, and stimulation of B-cells to undergo somatic hypermutation, 
immunoglobulin class switching, and proliferation.   Agonistic anti-CD40 antibodies have 
shown promising adjuvant qualities in human and mouse vaccine studies.   An antiCD40 
monoclonal antibody (mAb), designated 2E4E4, was identified and shown to have strong 
agonistic effects on primary cells from multiple livestock species.    The mAb recognize 
swine, bovine, caprine, and ovine CD40, and evoked 25 fold or greater proliferation of 
peripheral blood mononuclear cells (PBMCs) from these species relative to cells incubated 
with an isotype control (p<0.001).  In addition, the mAb induced significant nitric oxide 
(p<0.0001) release by bovine macrophages.  Furthermore, the mAb upregulated the 
expression of MHC-II by PBMCs, and stimulated significant (p<0.0001) IL-1α, IL-6, IL-
8, and TNF-α expression by PBMCs.   These results suggest that the mAb 2E4E4 can 
target and stimulate cells from multiple livestock species and thus, it is a potential 
candidate for adjuvant development.  This the first study to report an anti-swine CD40 
agonistic mAb that is also broadly reactive against multiple species.  
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1. INTRODUCTION*
Cluster of differentiation 40 (CD40) receptor belongs to the tumor necrosis factor 
superfamily and is expressed on B-cells, macrophages, dendritic cells (DCs), endothelial 
cells and fibroblasts[1-3].   The CD40 is also expressed on several types of human cancer 
cells including bladder, breast, and ovarian[4, 5].   A natural ligand for CD40, CD40L 
(CD154), is expressed by activated CD4+ T-cells[4, 6].   The CD40L interacts with CD40 
by crosslinking multiple CD40 molecules and thereby provides a critical signal for antigen 
presenting cells (APCs) activation [7, 8].   The CD40-CD40L interaction stimulates B-
cells to undergo somatic hypermutation, class switch recombination, clonal expansion, 
upregulation of Major histocompatibility complex II (MHC-II) and secretion of 
proinflammatory cytokines. For example, humans suffering from X linked hyper-IgM 
syndrome are deficient in either CD40 or CD40L, and thus do not undergo class switch 
recombination or somatic hypermutation. The X-linked hyper IgM syndrome leads to high 
proportions of IgMs and low levels of IgA, IgE, and IgG present in the serum, absence of 
germinal centers, and the inability to mount a T-cell-dependent humoral response[9].  The 
interaction of CD40L with CD40 on macrophages, induces synthesis and release of nitric 
* Reprinted with permission from “Characterization of a Broadly Reactive Anti-CD40
Agonistic Monoclonal Antibody for Potential Use as an Adjuvant” by Cameron Martin, 
Suryakant D. Waghela, Shehnaz Lokhandwala, Andy Ambrus, Jocelyn Bray, Christina 
Vuong, Vanitha Vinodkumar, Paul J. Dominowski, Sharath Rai, Duncan Mwangi, 
Dennis L. Foss, Waithaka Mwangi, 2017. PLoS ONE 12(1): e0170504. 
https://doi.org/10.1371/journal.pone.0170504, Copyright [2017] by Cameron Martin 
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oxide, upregulation of MHC-II expression, and secretion of proinflammatory 
cytokines[10, 11]. 
Naïve T-cells require two distinct signals from APCs for proper activation and induction 
of differentiation: signal 1 is provided by peptide antigens in the context of MHC 
molecules, while signal 2 is delivered by costimulatory molecules such as CD80 or CD86 
present on DCs[12].   For antigen-loaded DCs to provide these signals effectively, they 
require activation to up-regulate surface expression of MHC-peptide complexes and 
costimulatory molecules, and to secrete pro-inflammatory molecules such as IL-12 [13].   
The DC activation is an innate response that adjuvants as well as live vaccines stimulate 
through pattern recognition receptor (PRR)-ligand signaling, chemokine and cytokine 
secretion [14]. 
 
  Expression of CD80/CD86 is upregulated by PRR ligands, TNF-α and IFN-γ, as well as 
interaction between CD40 on APCs and CD40L [12-14]. Even though the DCs from 
CD40-/- or CD40L-/- mice present antigens on MHC class I and II molecules and express 
high levels of CD80/86, CD4+ and CD8+ T cell immunity is not elicited [13]. This 
indicates that distinct CD40/CD40L signaling that functions together with antigen 
presentation and co-stimulation is required to generate functional CD4+ T-helper and 
CD8+ -CTLs [13]. This signaling critically requires APC-T cell contact, CD40L 
expression, or an agonistic anti-CD40 antibody [15-17]. With regard to priming CD8+ 
CTLs, DCs are first activated by CD4+ T-helper cells through CD40CD40L interactions 
and they in turn activate CD8+ CTLs by, in part, secreting proinflammatory cytokines, 
such as IL-12. The secreted IL-12 is a powerful inducer of IFN-γ production and Th1 
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differentiation [18]. More importantly, DC activation through CD40 signaling overcomes 
tolerance and may release immature DCs from the control of regulatory CD4+ CD25+ T-
cells [19]. Agonistic mAbs against CD40 directly mimic CD4+ T-cell help in vivo in 
response to T-cell dependent antigens [20-23]. Using CD40-targeted antigen delivery, up 
to 1000-fold increased antibody responses has been reported [22, 24]. In vitro stimulation 
of APCs using various forms of CD40 agonists like membrane-associated CD40L, soluble 
CD40L (sCD40L), or anti-CD40 antibodies evokes distinct functional responses [25]. 
Conjugation of an agonistic anti-CD40 mAb to a peptide based vaccine, a whole killed 
virus vaccine, or a commercially produced split influenza virus vaccine significantly 
enhanced antigen-specific antibody and T-cell responses[26]. Antibody class switching is 
also attributed to such agonistic anti-CD40 antibodies following interaction with CD40 on 
B-cells [27]. Therefore, CD40 activation using a high affinity agonistic antibody is an 
attractive strategy for adjuvant development. The livestock industry is an economically 
important sector that generates revenue and jobs globally, but disease control is partly 
hindered by lack of safe and effective adjuvants [28]. In addition, livestock serve as 
models for infectious and non-infectious human diseases. Therefore, development and 
optimization of an agonistic anti-CD40 mAb is likely to result in generation of new 
adjuvants for use in livestock[29, 30]. In this study, we developed an anti- swine CD40 
mAb and characterized its agonistic activity on cells from livestock species.  
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2. METHODS AND MATERIALS*
2.1 Alignment of CD40 Sequences   
Swine (AAL92924.1), Bovine (NP_001099081.1), Ovine (NP_001068569.1), Caprine 
CD40 (XP_005688676.1), Human (NP_001241.1), Murine (AAH29254.1), Feline 
(XP_003983558.1),  Canine(NP_001002982.1), Cavine  (XP_013005826.1), and 
Erinaceine (XP_007533138.1) protein sequences were obtained from GenPept.  
Sequences were aligned using Jalview 2.9.0b2 and analyzed by Clustal X.  Homology 
between these CD40 protein sequences was calculated by Protein BLAST to determine 
percentage identity to swine CD40 sequence. 
  
2.2 Cell Culture  
Hybridomas, human embryonic kidney (HEK)-293A cells, and fresh peripheral blood 
mononuclear cells (PBMCs) were grown in an atmosphere of 5% CO2 at 37oC.   
Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum, GlutaMAX™(2mM), HEPES (0.01M), Penicillin-Streptomycin (100U/mL), 
nonessential amino acids (0.1M), sodium pyruvate (1mM), and 2-mercaptoethanol 
(0.1mM) was used to grow hybridomas.   HEK-293A cells were grown in DMEM 
* Reprinted with permission from “Characterization of a Broadly Reactive Anti-CD40
Agonistic Monoclonal Antibody for Potential Use as an Adjuvant” by Cameron Martin, 
Suryakant D. Waghela, Shehnaz Lokhandwala, Andy Ambrus, Jocelyn Bray, Christina 
Vuong, Vanitha Vinodkumar, Paul J. Dominowski, Sharath Rai, Duncan Mwangi, 
Dennis L. Foss, Waithaka Mwangi , 2017. PLoS ONE 12(1): e0170504. 
https://doi.org/10.1371/journal.pone.0170504, Copyright [2017] by Cameron Martin 
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supplemented with 10% FBS, GlutaMAX™, HEPES (0.01M), non-essential amino acids 
(0.1M), and 2mercaptoethanol (0.1M).   Fresh swine, bovine, caprine, and ovine PBMCs 
were cultured in RPMI 1640 supplemented with 10% FBS, GlutaMAX™, non-essential 
amino acids (0.1M), HEPES (0.01M), 2-mercaptoethanol (0.1M), and Penicillin-
Streptomycin (100U/mL). FreeStyle™ 293-F cells were grown in Freestyle™ Expression 
Media (ThermoFisher) in an atmosphere of 8% CO2 at 37oC.  
2.3 Generation and Purification of Recombinant Swine CD40 
Total RNA was isolated from swine spleen using Trizol® (Invitrogen, Carlsbad, CA) and 
used for cDNA synthesis using Superscript II reverse transcriptase (Invitrogen). 
Sequences encoding full-length swine CD40 (swCD40) or the extracellular domain 
(swCD40ED) was PCR amplified with Accuprime Pfx DNA Polymerase (Invitrogen) 
using primers based on GenBank sequence AF248545.1The PCR product encoding the 
swCD40ED was ligated into PCR-TOPO vector (Invitrogen), and the ligation mix was 
used to transform E. coli TOP 10 cells (Invitrogen). Following colony screening and DNA 
sequencing of positive clones, one construct encoding the authentic swCD40ED was 
modified by overlap extension PCR to incorporate a secretory signal sequence at the 5’ 
terminus and the FLAG-tag at the 3’-terminus. The resultant gene encoding the 
swCD40ED and the PCR product encoding full-length swCD40 were sub-cloned into the 
eukaryotic expression vector pcDNA3.1-TOPO (Invitrogen) and verified by sequencing. 
A construct encoding full-length bovine CD40 (boCD40) was similarly generated.  
Recombinant swCD40ED was expressed as a FLAG-tagged protein by transfecting HEK-
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293 Free-Style cells (Invitrogen) and affinity purified using anti-FLAG M2-agarose 
affinity chromatography (Sigma) as previously described [31, 32].  
2.4 Monoclonal Antibody Production  
Monoclonal antibodies (mAbs) against swCD40ED were produced as previously 
described [33]. Briefly, three female BALB/c mice were inoculated subcutaneously three 
times every 2 weeks with 50μg of recombinant swCD40ED in RIBI adjuvant 
(SigmaAldrich). The mice were housed under temperature controlled and lighting 
controlled conditions in specific pathogen-free (SPF) facility at Texas A&M University. 
Seroconversion was monitored on a weekly basis by ELISA using plates coated with the 
recombinant swCD40ED (100ng/well). The mouse with the best anti-swCD40ED 
antibody response was sedated by isoflurane and then stimulated by retro-orbital injection 
of 50μg of the recombinant swCD40ED without adjuvant. Three and five days prior to 
harvesting splenocytes, the mouse with the best anti-swCD40ED antibody response was 
stimulated by Retro-orbital injection of 50μg of the recombinant swCD40ED without 
adjuvant.    On the day of fusion, the spleen was harvested for preparing single cell 
suspension for electrofusion with Sp2/0 myeloma cells (ATCC, Manassas, VA). 
Hybridomas were plated in 96-well cell culture plates (Nunc) and grown in hypoxanthine-
aminopterin-thymidine (HAT) medium.   Primary screening was performed by ELISA on 
day 14 post-fusion using ELISA plates coated with recombinant swCD40ED as above. 
Proliferation assay was used to test ELISA-positive hybridomas for agonistic effect on 
swine PBMCs.  Positive hybridoma clones identified by proliferation assay were 
subcloned by limiting dilution and retested by ELISA and proliferation assays.   The 
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leading candidate, clone 2E4E4, was isotyped using the Mouse Immunoglobulin Isotyping 
ELISA Kit (BD Pharmingen) following the manufacturer’s protocol and was selected for 
further analysis.  
2.5 Immunocytometric Analysis  
HEK-293A cell monolayers were transfected with constructs encoding either swCD40 
(pcDNAswCD40) or boCD40 (pcDNAboCD40) using Polyethylenimine (Polyscience) as 
described by [34].   Following 48 hr. incubation, the monolayers were fixed with cold 
methanol, rinsed with PBS, blocked with 10% FBS/PBS solution, and incubated for 1 hr. 
at room temperature with 5µg/mL of the mAb 2E4E4 or 5µg/mL of an IgG1 isotype 
control (Biolegend). The cell monolayers were washed 3X with blocking buffer and then 
incubated for 1 hr.  with Alkaline Phosphatase AffiniPure F(ab)2 Fragment Donkey Anti-
Mouse IgG (H+L) (Jackson ImmunoResearch Laboratories, INC). Following washes as 
above, Fast Red TR–Naphthol AS-MX substrate (Sigma, F4523) was used to detect 
alkaline phosphatase activity.   Photos were captured using Spot RT3 camera on Olympus 
IX70 microscope.  
2.6 Flow cytometry    
2.6.1 Transfection of HEK-293A Cells   
The pcDNAswCD40 and pcDNAboCD40 constructs were used to transfect HEK-293A 
cell monolayers using Polyethylenimine (Polyscience) as previously described [34].   
Following 48 hr. incubation, one million transfected cells were added to each well of a 96 
well V-bottom plate and stained with Zombie RedTM Fixable Viability Kit (Biolegend) 
following the manufacture's protocol. The pcDNAswCD40 and pcDNAboCD40 
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transfected HEK-293A cells were incubated with 5µg/mL of the mAb 2E4E4 or 5µg/mL 
of IgG1 isotype control for 30 min and washed 3X with blocking buffer (cDMEM with 
0.05% sodium azide/20% bovine Serum). The cells were incubated for 30 min with 
AffiniPure F(ab’)2 Fragment Donkey Anti-Mouse IgG (H+L) conjugated with FITC 
(Jackson ImmunoResearch Laboratories, INC.), washed 3X with block buffer, and stored 
in FACS fixer (12.5% formaldehyde/PBS).   Data was collected using BD FACScalibur™ 
(Becton Dickinson) and data analysis was done using FlowJo 10 software (FlowJo). 
2.6.2 LPS Stimulated Swine and Bovine PBMCs  
A minimum of 30 mL of blood was collected from pigs, cows, goats, and sheep.  The 
blood was then processed to isolate PBMCs by Histopaque® (Sigma-Aldrich) density 
gradient centrifugation following the manufacturer’s protocol.   Swine and bovine PBMCs 
were added to a 12 well plate (4 million PBMCs per well) and incubated for 24 hr. in 1mL 
of complete RPMI alone or in cRPMI containing LPS (10µg/mL).  Half a million swine 
or bovine PBMCs from either treatment was added to each well of a 96 well v-bottom 
plate (Axygen), stained with zombie redTM viability kit (Biolegend) following 
manufacturer’s protocol, and blocked using either swine blocking buffer (cRPMI with 
0.05% sodium azide/20% swine serum) or bovine blocking buffer (cRPMI with 0.05% 
sodium azide/20% bovine serum).   The swine and bovine PBMCs were incubated for 30 
min on ice with either 5µg/mL of the mAb 2E4E4-FITC or 5µg/mL of IgG1 isotype 
control (Biolegend) conjugated to FITC, washed 3X with blocking buffer, and fixed using 
FACS Fixer.   Flow cytometry data was collected and analyzed as above.   
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2.6.3 MHC Class II Expression  
Swine PBMCs were seeded in a 12 well plate at 4 million PBMCS per well in 1mL of 
cRPMI media alone, media containing LPS (10µg/mL), or media containing graded 
amounts of the mAb 2E4E4 (0.5, 1.0, 2.5, 5.0µg/mL).   After a 24 hr. incubation, half a 
million PBMCs were added to each well of a 96 well v-bottom plate (Axygen), blocked 
(20% swine serum/FACS media) for 30 min on ice, and then incubated for 30 min with  
5µg/mL of mouse anti-swine MHCII-FITC clone MSA3 (Monoclonal Antibody Center 
Washington State University).   The PBMCs were washed 3X with blocking buffer, and 
then fixed and stored in FACS fixer.   Flow cytometry data was collected and analyzed as 
above.   
2.7 Immunohistochemistry   
Swine, bovine, caprine, ovine, feline, erinaceine, and cavine spleen tissue and canine 
lymph node tissue (donated by Texas A&M Veterinary Medical Diagnostic Laboratory) 
were used to prepare histology slides as previously describ. A Intellipath (Biocare 
Medical) automated immunohistochemistry slide staining system was used to stain the 
slides by following the protocol described below. The slides were incubated for 20 min. 
with Peroxidazed 1 (Biocare Medical), washed with TBS 1X for 15 secs, and incubated 
with Background Sniper (Biocare Medical) for 20 min.   After washing as described above, 
the slides were incubated with 5µg/mL of the mAb 2E4E4 or 5µg/mL of IgG1 isotype 
control.   Following 1 hr. incubation, the slides were washed 1X with TBS and incubated 
for 1 hr. with ImmpressTM Goat Anti-Mouse IgG Serum-HRP (Vector) secondary 
antibody.   After washing the slides as described above, Horseradish peroxidase activity 
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was tested using Nova Red (Vector Labs) and then counter-stained with crystal violet. 
Photos were captured using Spot RT3 camera on Olympus IX70 microscope.  
2.8 Proliferation Assay  
Swine, bovine, caprine, and ovine PBMCs (250,000 cells/well) were cultured in triplicate 
wells of 96 well round bottom plates for 24 hr. in a total volume of 100µL of cRPMI 
containing graded amounts of the mAb 2E4E4 (0.5, 1.0, 2.5, 5.0, or 10µg/mL), IgG1 
isotype control (0.5, 1.0, 2.5, 5.0, or 10 µg/mL), PMA (1µg/mL)/Ionomycin (0.5µg/mL), 
or media alone.    The cells were labeled for 12 hr. with 0.3 µCi of 3Hthymidine and 
incorporation of the isotope (in counts per minute) by the cells was determined using 
Microbeta Counter (PerkinElmer).   Stimulation index (SI) was calculated from the CPM 
data for both 2E4E4 and IgG1 isotype control by dividing the treatment (2E4E4 or IgG1 
isotype control) by the media control.  
2.9 Nitric Oxide Assay   
The level of nitrite (NO2-) released by activated bovine monocyte-derived macrophages 
was measured by a Griess assay as previously described [35].   Briefly, the macrophages 
(200,000 cells/well) were added in triplicate wells of a 96 well flat bottom plate containing 
graded amounts of the mAb 2E4E4 (0.5, 1.0, 2.5, 5.0, 10µg/mL), IgG1 isotype control 
(0.5, 1.0, 2.5, 5.0, 10µg/mL), LPS (10µg/mL), or media alone.   Following a 24 hr. 
incubation, macrophage supernatants were tested for nitrite concentration using Nitric 
Oxide Assay kit (ThermoFisher) following manufacturer’s protocol.    Nitrite released was 






2.10 Intracellular Cytokine Staining   
For intracellular cell cytokine staining, swine PBMCs (4 million cells) were added to each 
well of a 12 well plate containing graded amounts of the mAb 2E4E4 (1.0, 2.5µg/mL), 
LPS (1µg/mL) or media alone.   The cells were incubated for either 12 hr. or 24 hr., and 
12 hr. before cells were harvested, Brefeldin A was added to each well.   The PBMCs were 
plated in 96 well v-bottom plate (5 x 105 cells/well), incubated for 15 min in 
PERM/WASH™, blocked (20% porcine serum in 1X PERM/WASH™ buffer), and 
further incubated with 5µg/mL of mouse anti-swine TNF-α clone 103314 (R&D  
Systems) conjugated with FITC, mouse anti-swine IL-1α clone 85733.11 (R&D Systems) 
conjugated with FITC, mouse anti-swine IL-6 clone 77830 (R&D Systems) conjugated 
with FITC, or mouse anti-swine IL-8 Clone 105115 (R&D Systems) conjugated with FITC 
for 1hr.  After 3 washes with blocking buffer, the cells were fixed and stored in FACS 
fixer.   Flow data was collected, and analyzed as above.  
2.11 Statistics 
All analyses were performed using GraphPad 6.05 software.   Data from the nitric oxide 
assay was analyzed by two-way ANOVA with Sidak's multiple comparisons test 
comparing similar concentrations of 2E4E4 to IgG1 isotype control.   The proliferation 
assay data was analyzed by two-way ANOVA with post-hoc Tukey’s multiple 
comparisons tests comparing similar concentrations of 2E4E4 to IgG1 isotype control.   
Intracellular cytokine data was also analyzed by two-way ANOVA with Dunnett’s test 
multiple comparisons by comparing the media control to the treatment from the same time 
point.   MHC-II flow cytometry data was tested for correlation between PBMCs incubated 
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with mAb 2E4E4 and by the MHC-II positive percentage by performing a one-tailed 
Spearman correlation test.   A value of p≤0.05 was considered statistically significant.   
2.12 Ethics Statement  
The study was conducted in accordance with the Public Health Service Policy on 
Humane Care and Use of Laboratory Animals as specified in the Health Research and 
Extension Act of 1985 (Public Law 99–158) or in accordance with the U.S Department 
of Agriculture policies as required by the Animal Welfare Act of 1966 (7.USC.2131 et 
seq) as amended in 1970, 1976, and 1985. The research protocol: AUP 2013–0092 was 
reviewed and approved by the Texas A&M University Institutional Animal Care and 
Use Committee to ensure compliance with PHS standards. All animal care facilities are 
inspected twice per year. The facilities and procedures for maintenance and care of 
animals are accredited by the American Association for Accreditation of Laboratory 
Animal Care. Efforts were made to minimize suffering, and at the completion of the 
study, the mice were euthanized by CO2 narcosis followed by cervical dislocation. This 
method is approved by the Panel on Euthanasia of the American Veterinary Medical 
Association. Porcine, bovine, ovine, caprine, canine, feline, cavy, and erinaceine tissues 
and cells were acquired from the Texas A&M University tissue share program. Porcine, 
bovine, ovine, and caprine tissues and cells were acquired from the Texas A&M 
University tissue share program.  
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3. RESULTS AND DISCUSSION*
3.1 The mAb 2E4E4 Recognized Cell-Surface Expressed CD40    
A mouse anti-swine CD40 mAb, designated 2E4E4, was generated by immunizing mice 
using recombinant extracellular domain of swine CD40 (Fig. 1).  The isotype of mAb 
2E4E4 was determined to be IgG1k.   Immunocytometric analysis of HEK-293A cells 
transfected with a construct expressing full length swine CD40 confirmed that the mAb  
2E4E4 recognized CD40, whereas sham treated cells were negative (Fig. 2B and 2D). 
This outcome was also confirmed by performing flow cytometry on similarly transfected 
cells.   The mAb 2E4E4, but not IgG1 isotype control, strongly recognized surface 
expressed swine CD40 (Fig. 2E).   Since swine and bovine CD40 protein sequences are 
highly conserved (Fig 1.), we predicted that mAb 2E4E4 could also bind to bovine CD40. 
Indeed, immunocytometric and flow cytometric analysis of HEK-293A cells transfected 
with a construct expressing full length bovine CD40 yielded similar results (Fig. 2C and 
F).   These outcomes showed that the mAb 2E4E4 could bind to both swine and bovine 
CD40, and hence all further experiments were designed to evaluate the interaction of the 
mAb 2E4E4 with bovine CD40 as well. 
* Reprinted with permission from “Characterization of a Broadly Reactive Anti-CD40
Agonistic Monoclonal Antibody for Potential Use as an Adjuvant” by Cameron Martin, 
Suryakant D. Waghela, Shehnaz Lokhandwala, Andy Ambrus, Jocelyn Bray, Christina 
Vuong, Vanitha Vinodkumar, Paul J. Dominowski, Sharath Rai, Duncan Mwangi, 
Dennis L. Foss, Waithaka Mwangi , 2017. PLoS ONE 12(1): e0170504. 
https://doi.org/10.1371/journal.pone.0170504, Copyright [2017] by Cameron Martin 
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Figure 1. Bovine, ovine, caprine, murine, and human CD40 protein sequences have 
high homology to swine CD40 protein sequence.   
Alignment of swine, bovine, ovine, caprine, human, and murine amino acid sequences. 
The signal sequence is shown where the consensus sequence is highlighted in green 
(amino acid 1-19), whereas the consensus sequence of the transmembrane domain is 
highlighted in red (amino acid 192-215).   The percentage identity of the extracellular 
domains of bovine, ovine, caprine, human, and murine CD40 protein sequences to that of 
swine is 74%, 75%, and 75%, 73%, and 57% respectively 
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3.2 The mAb 2E4E4 Recognized Native Swine and Bovine CD40  
Flow cytometric analysis showed that the mAb 2E4E4 bound to the CD40 expressed on 
LPS-stimulated swine and bovine PBMCs. The mAb 2E4E4 showed fluorescence on 
stimulated PBMCs as compared to non-stimulated controls. A specific signal was also 
detected on non-stimulated PBMCs probed with the mAb 2E4E4, but not on cells probed 
Figure 2. Reactivity of the mAb 2E4E4 against HEK 293A cells expressing swine or 
bovine CD40.   
Evaluation of the mAb 2E4E4 specificity against swine and bovine CD40 was performed 
by immunocytometric analysis: A) Analysis of mAb 2E4E4 and a defined IgG1 control 
mAb by PAGE; B) HEK 293A cells transfected with a construct expressing full length 
swine CD40 and probed with 2E4E4; C) HEK 293A cells transfected with a construct 
expressing full length bovine CD40 and probed with the mAb 2E4E4; and D) Sham treated 
HEK 293A cells probed with the mAb 2E4E4.  Flow cytometric analysis performed on: 
E) HEK 293A cells transfected with a construct encoding full length swine CD40; or F)
full length bovine CD40 probed with either the mAb 2E4E4 (Red)or IgG1 isotype control 
(Blue).  
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with an IgG1 isotype control (Fig. 3).   These results showed that the mAb 2E4E4 bound 
to the CD40 expressed on the cell surface of stimulated PBMCs.  These outcomes are 
consistent with previous findings which showed that PBMCs upregulate CD40 on their 
cell surface when stimulated with LPS [36]. In addition, immunohistochemistry (IHC) 
showed that mAb 2E4E4, but not an IgG1 isotype control, reacted strongly to swine and 
bovine spleen tissues (Fig. 4 A-B and E-F).   Taken together, the flow cytometry and IHC 
data showed that the mAb 2E4E4 recognized CD40 expressed on swine and bovine cells.   
In addition, IHC data also showed cross-reactivity of the mAb 2E4E4 to caprine and ovine 
Figure 3. The mAb 2E4E4 recognized CD40 on stimulated swine and bovine PBMCs 
Flow cytometry performed on A) swine and B) bovine PBMCs stimulated (Gold) or not 
stimulated (Red ) with LPS and probed with the mAb 2E4E4.  IgG1 isotype control (Blue) 
was also used to probe LPS-stimulated swine and bovine PBMCs.   
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CD40 (Fig. 4C-D). Surprisingly, staining was also observed on spleen tissues from feline, 
cavine, and erinaceine and lymph node tissue from canine (Fig. 5). These result surprised 
us as cavine and erinaceine protein sequences had less than 65% identity to swine CD40, 
while the other species had CD40 protein sequences around 70% or more identity. CP 
870,893 is an agonistic anti-human CD40 mAb that is currently being used in clinical 
trials.  Interestingly, CP 870,893 did not show any agonistic affect against mice, rat, rabbit, 
or dog cells, while mAb 2E4E4 was able to bind to canine cells [37]. This data shows the 
unique species range mAb 2E4E4 can recognize.  Although mAb 2E4E4 was shown to 
have cross-reactivity against multiple species, it did not react with human macrophage cell 
Figure 4. Validation of the specificity of the mAb 2E4E4 against CD40 expressed in  
swine, bovine, ovine, and caprine spleen.  Immunohistochemistry performed on:  A) 
swine; B) bovine; C) ovine; and D) caprine spleen tissues probed with the mAb 2E4E4. 
Background reactivity was tested by probing E) swine, F) bovine, G) ovine, and H) caprine 
spleen tissues with an IgG1 isotype control mAb.   
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lines but studies with primary human cells are yet to be done. Given this outcome, it is 
likely that mAb 2E4E4 recognizes a CD40 determinant that is distinct from the one 
recognized by anti-human CD40 mAbs.  This outcome is supported by the observation 
that no anti-human CD40 mAbs cross-reacts with swine CD40. 
Figure 5. Validation of the specificity of the mAb 2E4E4 against CD40 expressed in 
swine, feline, canine, erinaceine, and cavine.  Immunohistochemistry performed on:  A. 
feline, B. cavine, D. erinaceine spleen, and B. canine Lymph node tissues probed with the 
mAb 2E4E4.   Background reactivity was tested by probing E. feline, G. cavine, and H. 
erinaceine spleen and F. canine lymph node tissues with an IgG1 isotype control mAb.  
3.3 Agonistic Effect of mAb 2E4E4   
The mAb 2E4E4 showed significant agonistic effects on swine, bovine, caprine, and ovine 
PBMCs. The mAb 2E4E4 stimulated significant (p<0.001) proliferation of swine and 
bovine PBMCs compared to the IgG1 isotype control (Fig. 6A-B).  Interestingly, the mAb 
2E4E4 also had significant stimulatory (p<0.001) effect on ovine and caprine PBMCs in 
a dose dependent manner (Fig. 6C-D).    The stimulatory effect is consistent with previous 
19 
findings that showed that an agonistic anti-human CD40 mAb named CP 870,893 
activated proliferation of human lymph node cells.  Further evidence of the agonistic effect 
of mAb 2E4E4 was shown by demonstrating that the mAb, but not an IgG1 isotype 
control, stimulated significant (p<0.0001) NO release by bovine macrophages (Fig. 7).  
Figure 6. Stimulation of swine and bovine PBMC proliferation by the mAb 2E4E4   
Agonistic activity of the mAb 2E4E4 on swine, bovine, ovine, and caprine PBMCs was 
evaluated by 3H-Thymidine incorporation.   Panels: A) swine, B) bovine, C) ovine, and 
D) caprine PBMCs responses after incubation with 2E4E4 (representative data is shown
for 3 animals from each species) or an IgG1 isotype control.  Each point represents the 
mean stimulation index from triplicate wells ± SD; *Significant (p<0.001) mAb 
2E4E4induced proliferation of PBMCs from all the three 3 animals compared to IgG1 
isotype control treatment.   
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We also tested NO production by swine macrophages, but the outcome was negative. 
Previous studies showed that swine macrophages stimulated with agonists, such as LPS, 
do not transcribe nitric oxide synthase mRNA and thus do not synthesize nitric oxide, and 
this outcome is consistent with our observation [38-40]. Flow cytometry confirmed that 
the mAb 2E4E4 upregulated MHC-II expression on swine PBMCs. A significant increase 
(p<0.01) in MHC-II expression was observed when swine PBMCs were stimulated with 
the mAb 2E4E4 and the response was dose dependent (Table 1). The MHC-II upregulation 
is expected to result in enhanced antigen presentation by APCs as has previously been 
shown [41, 42]. The agonistic effect of mAb 2E4E4 was further investigated by 
intracellular cytokine staining. Significant (p<0.01) upregulation of TNF-α, IL-1α, and IL- 
8 was observed at 12hr. post-stimulation (Fig 8A–7C). 
Table 1. MHC-II upregulation by swine PBMCs stimulated with the mAb 2E4E4 
Swine PBMCs were incubated with the mAb 2E4E4 or LPS for 24hr. and MHC-II 
upregulation was determined by flow cytometric analysis.  Data is presented as absolute 
percentage of MHC-II positive cells compared to IgG1 isotype control. 
Sample MHCII % positive 
cells  
LPS  19.0 








5 µg/mL (2E4E4)  22.2 
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No significant expression of IL-1 α or IL-8 was detected after incubating the PBMCs with 
mAb 2E4E4 for 24 hr.   Significant (p<0.001) expression of TNF-α was observed at 24 
hr. but at a lower level of expression than seen at 12hr.  Unlike TNF-α, IL-1α, and IL-8, 
significant (p<0.001) IL-6 expression was observed for 1µg/mL of mAb 2E4E4 after 24hr. 
post-stimulation (Fig. 8D).  
Figure 7. Stimulation of Nitric oxide response by mAb 2E4E4.   
Agonistic effect of 2E4E4 was verified by Nitric oxide assay using bovine monocyte 
derived macrophages incubated with graded amount of the mAb 2E4E4 (Red) or IgG1 
isotype control mAb (Blue).   Each column represents the µM of NO2-  mean of triplicate 
wells stimulated with the mAb 2E4E4 at each concentrations ± SD; n=3; * P<0.0001.
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PBMCs incubated with 2.5 µg/mL of mAb 2E4E4, however, had significantly (p<0.05) 
upregulated IL-6 at 12hr. and continued to upregulate IL-6 at 24 hr.  This delay in 
expression of IL-6 is consistent with previous findings [43, 44]. 
Figure 8. Upregulation of pro-inflammatory cytokine response by mAb 2E4E4  
Intracellular cytokine staining was used to evaluate the ability of mAb 2E4E4 to stimulate 
upregulation of pro-inflammatory cytokines.   Swine PBMCs were incubated with the 
mAb 2E4E4, LPS, or media alone, harvested at 12 hr. (Black) and 24 hr. (Gray), and then 
probed with mAbs against A) IL-1α; B) TNF-α; C) IL-6; or D) IL-8.  Each column 
represents the mean florescent intensity of two wells ± SD. *p<0.05  
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Upregulation of MHC-II and proinflammatory cytokines have previously been shown to 
be important signals for stimulation of an adaptive immune response against a vaccine. 
These studies have reported that MHC-II signaling is required for CD4+ T-cell and APCs 
activation, while pro-inflammatory cytokines such as IL-6 are important for activating the 
immune system and modulating TH1/TH2 responses [45-47].   Our results showed that 
the mAb 2E4E4 can stimulate upregulation of MHC-II and release of pro-inflammatory 
cytokines, thus suggesting that the mAb 2E4E4 has several activities that would be 
beneficial as a vaccine adjuvant.  
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4. CONCLUSION*
In summary, an anti-swine CD40 mAb, designated 2E4E4, was generated, characterized 
and demonstrated to be cross-reactive to bovine, ovine and caprine CD40.  The mAb 
2E4E4 was shown to specifically bind to CD40 on swine and other species including 
bovine, caprine, and ovine.   In addition to the mAb 2E4E4 having agonistic effects on 
swine cells, it also showed broad agonistic effects against bovine, caprine, and ovine cells. 
These outcomes suggest that mAb 2E4E4 has a potential for development of a broad 
immune modulator for use in livestock.   Agonistic anti-CD40 mAb is a more attractive 
stimulant for adjuvant development compared to other CD40 agonist such as recombinant 
CD40L or C3-sysmmetric complex since, a previous study that utilized these agonists 
reported that agonistic anti-mouse CD40 mAb (3/23) had a 2-fold increase in B-cell 
proliferation compared to CD40L.  While C3-sysmmetric complex showed no agonistic 
activity when added to mouse PBMCs, it had synergistic effect when mixed with agonistic 
anti-CD40 mAb [48].   Immune modulators, such as CP-870,893 (an antihuman CD40 
mAb), recently been shown to be useful in treating a broad range of cancers and function 
as a strong adjuvant component [49, 50] .  Patients who have received agonistic anti-CD40 
* Reprinted with permission from “Characterization of a Broadly Reactive Anti-CD40
Agonistic Monoclonal Antibody for Potential Use as an Adjuvant” by Cameron Martin, 
Suryakant D. Waghela, Shehnaz Lokhandwala, Andy Ambrus, Jocelyn Bray, Christina 
Vuong, Vanitha Vinodkumar, Paul J. Dominowski, Sharath Rai, Duncan Mwangi, 
Dennis L. Foss, Waithaka Mwangi , 2017. PLoS ONE 12(1): e0170504. 
https://doi.org/10.1371/journal.pone.0170504, Copyright [2017] by Cameron Martin 
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have shown an increase in memory CD8+ CTLs, CD27+ memory B-cells, and 
CD27+/CD86+ memory B-cells [51, 52]. An adjuvant that increases memory B-cells and 
CD8 memory T-cells would potentiate vaccines to confer better immune protection 
against broad range of diseases.   Unlike most of the immune modulators that are currently 
in use, a broad spectrum immune modulator, such as mAb 2E4E4, that can be used in a 
variety of animals will be a valuable resource in the development of new treatments and 
vaccines for livestock diseases [37].
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